Scarica l'app Stockscreener
6.88
5.36%
0.35
Pre-mercato:
7.21
0.33
+4.80%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$6.53
Aprire:
$6.74
Volume 24 ore:
12.70M
Relative Volume:
1.09
Capitalizzazione di mercato:
$2.69B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-4.4387
EPS:
-1.55
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
+8.86%
1M Prestazione:
+14.10%
6M Prestazione:
-9.59%
1 anno Prestazione:
-28.56%
Intervallo 1D:
$6.6641
$7.17
Intervallo di 1 settimana:
$6.33
$7.17
Portata 52W:
$5.60
$15.74
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Confronta RXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
6.88 | 2.69B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
(RXRX) Investment Analysis - Stock Traders Daily
Recursion posts mid-stage data for lead asset - MSN
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 - MSN
Avanza Fonder AB Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth - Insider Monkey
Blackrock’s 30 Most Important AI Stocks - Insider Monkey
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.5%Still a Buy? - MarketBeat
Is Recursion Pharmaceuticals Stock a Buy? - MSN
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.6%Should You Sell? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.5% HigherStill a Buy? - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.8%What's Next? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 4.4% HigherTime to Buy? - MarketBeat
JPM25: Recursion $RXRXby AlbertRhymes with Haystack - substack.com
Why Recursion Pharmaceuticals Shares Are Dropping - TipRanks
Recursion Pharmaceuticals CEO sells shares worth $287,200 By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals CEO sells shares worth $287,200 - Investing.com India
Recursion Pharmaceuticals Showcases Progress at JP Morgan Conference - TipRanks
Recursion Pharmaceuticals: Betting Big On AI (NASDAQ:RXRX) - Seeking Alpha
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect? - MSN
Long Term Trading Analysis for (RXRX) - Stock Traders Daily
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.3%Time to Sell? - MarketBeat
Recursion: Investors Will Need To Be Patient (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.1% Following Analyst Downgrade - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $10.00 by Analysts at KeyCorp - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.4%Time to Sell? - MarketBeat
Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA - Yahoo Finance
Recursion advances two cancer drug trials By Investing.com - Investing.com Australia
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.4%Should You Sell? - MarketBeat
Stock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX) - MarketBeat
Recursion advances two cancer drug trials - Investing.com
RXRXRecursion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.9%Time to Buy? - MarketBeat
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference - Marketscreener.com
Recursion CEO to Present Pipeline and Platform Updates at JP Morgan Healthcare Conference - StockTitan
Iambic Therapeutics Taps Former Recursion CFO to Lead Financial Strategy and Development - StockTitan
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.3% HigherShould You Buy? - MarketBeat
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):